Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

3(42.9%)

Phase 2

3(42.9%)

Phase 3

1(14.3%)

7Total

Phase 1(3)

Phase 2(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05947890Phase 2Recruiting

Evaluating the Safety and Immunogenicity of MTBVAC

Role: collaborator

NCT03536117Phase 2Completed

Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates

Role: lead

NCT04975178Phase 3Recruiting

Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa

Role: lead

NCT02933281Phase 1Completed

MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa

Role: collaborator

NCT03767946Completed

Epidemiological Study In Tuberculosis-Endemic Urban Area in Senegal

Role: collaborator

NCT03982797Phase 2Unknown

Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis

Role: lead

NCT02729571Phase 1Completed

Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults

Role: lead

NCT02013245Phase 1Completed

Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine.

Role: lead

All 8 trials loaded